View Discovery

Clinical Pipeline

Learn more about our pipeline

Trials for Market Approval Download PPT

Pre-Clinical (GLP)


GlaxoSmithKline, Bill & Melinda Gates Foundation
Foundation for Neglected Disease Research
Institute of Materia Medica, CAMS & PUMC
National Centre of Oceanic and Antarctic Research (NCAOR), Gao, India
Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
GlaxoSmithKline
Microbiotix, Inc.

Phase 1


TB Alliance, ERA4TB (European Regimen Accelerator for Tuberculosis), University of Auckland, Merck & Co., Inc.
TB Alliance, Institute of Materia Medica
GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation
iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
Institute of Materia Medica, CAMS & PUMC

Phase 2


Shanghai Jiatan Biotech Ltd., subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China
University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University
PanACEA, EDCTP, NIAID, NIH, DHHS, USAID
Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute
Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
TB Alliance, Bill & Melinda Gates Medical Research Institute, Foundation for Neglected Disease Research
Sequella, Inc
NIAID, NIH, DHHS, Bill & Melinda Gates Foundation, EDCTP